lncRNA-ATB/miR-141-3p/GP73轴介导EMT促进TACE抵抗的研究进展  

Research Progress of lncRNA-ATB/miR-141-3p/GP73 Ax-is-Mediated EMT Promoting TACE Refractoriness

作　　者：耿棋 朱帝文[1] 任伟新[1] 

机构地区：[1]新疆医科大学第一附属医院介入放射科,新疆 乌鲁木齐

出　　处：《临床医学进展》2024年第1期903-910,共8页Advances in Clinical Medicine

摘　　要：经导管动脉化疗栓塞(TACE)广泛应用于中晚期肝癌的治疗。然而,反复的TACE治疗并非总能对预后产生积极影响,部分学者将此现象称为TACE抵抗。由于定义的模糊和关键性证据不足,TACE抵抗的概念尚存争议。前有研究表明,上皮–间充质转化(EMT)是肝癌复发转移的重要原因,而肝癌的转移或许是TACE抵抗发生的潜在机制之一,故本文主要讨论TACE抵抗的相关研究,特别关注了GP73、miR-141-3p、lncRNA-ATB等介导EMT潜在促使TACE抵抗发生的研究进展,期望为中晚期肝癌治疗提供新靶点和理论基础。Transcatheter arterial chemoembolization (TACE) is widely used in the treatment of advanced liver cancer. However, repeated TACE treatment does not always have a positive effect on prognosis, some scholars refer to this phenomenon as TACE refractoriness. The concept of TACE refractoriness remains controversial due to vague definitions and lack of critical evidence. Previous studies have shown that epithelial-mesenchymal transformation (EMT) is an important cause of liver cancer re-currence and metastasis, and liver cancer metastasis may be one of the potential mechanisms of TACE refractoriness. Therefore, this paper mainly discusses relevant studies on TACE refractoriness. Special attention was paid to the research progress of GP73, miR-141-3p, lncRNA- ATB, etc. mediat-ing EMT and potentially promoting TACE refractoriness, hoping to provide new targets and theoret-ical basis for the treatment of middle and advanced liver cancer.

关 键 词：肝癌 经导管动脉化疗栓塞抵抗 GP73 lncRNA-ATB miR-141-3p 

分 类 号：R73[医药卫生—肿瘤]